
Tilray Brands, Quantum Biopharma, and Canopy Growth are the three Cannabis stocks to watch today, according to MarketBeat’s stock screener tool. Cannabis stocks are shares of publicly traded companies that operate in the cannabis industry, including businesses involved in growing, processing, distributing, or selling marijuana and hemp-related products. For stock market investors, these stocks are typically viewed as a sector play tied to changing laws, consumer demand, and regulatory developments. These companies had the highest dollar trading volume of any Cannabis stocks within the last several days.
Tilray Brands (TLRY)
Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc. is headquartered in Canada.
Quantum Biopharma (QNTM)
Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company’s three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS.
Read Our Latest Research Report on QNTM
Canopy Growth (CGC)
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments.
Read Our Latest Research Report on CGC
Recommended Stories
- MarketBeat’s Top Five Stocks to Own in May 2026
- The Great SPR Arbitrage: An Oil Market Glitch Fuels Sector Gains
- Why Satellogic Could Be One of the Biggest Space Winners of 2026
- A New Focus for GoPro: Is a Takeover in the Frame?
- Palantir’s Critics Are “Right”—But They’re Also Still Wrong
- Chime Finally Turns Profitable—But Risks Remain
